Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Cancer Gene Therapy|April 19, 2008
Primary neural stem/progenitor cells expressing endostatin or cytochrome P450 for gene therapy of glioblastomaA Lorico, J Mercapide, V Solodushko, et al.
Cancer Research|December 11, 1997
Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathioneA Lorico, G Rappa, R A Finch, et al.
Cancer Research|October 1, 1991
Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell linesB H Long, L Wang, A Lorico, et al.
British Journal of Cancer|December 1, 1986
Mitozolomide activity on human cancer cells in vitroE Erba, S Pepe, P Ubezio, et al.
Cancer Research|October 1, 1995
Increased rate of adenosine triphosphate-dependent etoposide (VP-16) efflux in a murine leukemia cell line overexpressing the multidrug resistance-associated protein (MRP) geneA Lorico, G Rappa, S Srimatkandada, et al.
Biochemical Pharmacology|October 6, 1997
Overexpression of the multidrug resistance genes mdr1, mdr3, and mrp in L1210 leukemia cells resistant to inhibitors of ribonucleotide reductaseG Rappa, A Lorico, M C Liu, et al.
Neuroscience|March 18, 2004
Efficient expansion and gene transduction of mouse neural stem/progenitor cells on recombinant fibronectinG Rappa, D Kunke, J Holter, et al.
Biochemical Pharmacology|July 19, 1994
Inhibitors of ribonucleotide reductase. Comparative effects of amino- and hydroxy-substituted pyridine-2-carboxaldehyde thiosemicarbazonesJ G Cory, A H Cory, G Rappa, et al.
Advances in Enzyme Regulation|January 1, 1995
Structure-function relationships for a new series of pyridine-2-carboxaldehyde thiosemicarbazones on ribonucleotide reductase activity and tumor cell growth in culture and in vivoJ G Cory, A H Cory, G Rappa, et al.
Cancer Journal (Sudbury, Mass.)|October 19, 2000
Phase I and pharmacokinetic study of novobiocin in combination with VP-16 in patients with refractory malignanciesJ R Murren, S A DiStasio, A Lorico, et al.
Pageof 4